Henrik L. D. F.
- Country
- Denmark
- Department
- Neurology
Research Overview
Data & Insights
Has run more than one trial at 0 of 11 partner sites.
Specializations
Cerebrovascular and Stroke Prevention
Focus on acute and secondary prevention of ischemic events in patients with recent stroke or high‑risk transient ischemic attack.
- Acute non‑cardioembolic ischemic stroke
- High‑risk transient ischemic attack
- Covert brain infarction
- Antiplatelet therapy combined with lipid lowering
- Factor Xa inhibition and thrombolysis
Investigations assess both efficacy in reducing recurrent stroke and safety regarding major bleeding.
Renal and Glomerular Disorders
Investigation of therapeutic strategies for focal segmental glomerulosclerosis and end‑stage renal disease.
- Novel agents for FSGS
- Renal function preservation (eGFR slope)
- ARB background therapy integration
- Proteinuria reduction outcomes
- Management of chronic kidney disease progression
Outcomes include proteinuria reduction and slowing of renal decline.
Infectious Disease and Sepsis
Evaluation of antimicrobial and immune‑modulating interventions for severe viral infections and bacterial sepsis.
- COVID‑19 immune modulation strategies
- Meropenem versus piperacillin/tazobactam in sepsis
- Duration of therapy for Staphylococcus aureus bacteremia
- Oral step‑down therapy for pyogenic vertebral osteomyelitis
- Antibody therapies for hepatitis B and D
Primary endpoints target mortality, clinical cure, and prevention of progression to organ failure.
Cardiovascular Arrhythmia and Anticoagulation
Study of anticoagulant and antiplatelet regimens in atrial fibrillation, including patients receiving dialysis.
- Warfarin safety and efficacy in dialysis
- Asundexian versus apixaban for stroke prevention
- ISTH major bleeding risk assessment
- Oral FXIa inhibition after ischemic stroke
- Combination antiplatelet and statin therapy
Research balances thrombotic protection with hemorrhagic safety.
Urology and Bladder Dysfunction
Clinical trials addressing daytime urinary incontinence and overactive bladder across age groups.
- Solifenacin monotherapy
- Mirabegron monotherapy
- Combination therapy of solifenacin and mirabegron
- Abrupt versus phased withdrawal effects
- Pediatric incontinence management (5‑14 years)
Efficacy measured by reduction in incontinence episodes and quality‑of‑life improvement.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.